Patents by Inventor Anton Leighton
Anton Leighton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220088047Abstract: The present invention is directed to methods for treating Dupuytren's disease, osteoarthritis, and adhesive capsulitis. The method comprises the steps of identifying a subject in need thereof, and administering to the subject an effective amount of one or more rhamnolipids, optionally in combination with niclosamide. A pharmaceutical composition comprising rhamnolipids, optionally in combination with niclosamide or a salt thereof, can be applied by any accepted mode of administration including oral, topical, or injection within or around the affected body part such as an affected hand, knee, or shoulder.Type: ApplicationFiled: December 3, 2021Publication date: March 24, 2022Inventors: Anton Leighton, Ralph T. SALVAGNO
-
Patent number: 9968626Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.Type: GrantFiled: August 14, 2015Date of Patent: May 15, 2018Assignee: Rhamnopharma Inc.Inventor: Anton Leighton
-
Publication number: 20160184337Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.Type: ApplicationFiled: August 14, 2015Publication date: June 30, 2016Inventor: Anton LEIGHTON
-
Patent number: 9107930Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.Type: GrantFiled: June 26, 2014Date of Patent: August 18, 2015Assignee: RHAMNOPHARMA INC.Inventor: Anton Leighton
-
Patent number: 9023815Abstract: The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant.Type: GrantFiled: November 25, 2013Date of Patent: May 5, 2015Assignee: Rhamnopharma Inc.Inventor: Anton Leighton
-
Publication number: 20150051162Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.Type: ApplicationFiled: June 26, 2014Publication date: February 19, 2015Inventor: Anton LEIGHTON
-
Patent number: 8765694Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.Type: GrantFiled: July 19, 2013Date of Patent: July 1, 2014Assignee: Rhamnopharma Inc.Inventor: Anton Leighton
-
Publication number: 20140080771Abstract: The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant.Type: ApplicationFiled: November 25, 2013Publication date: March 20, 2014Applicant: Rhamnopharma Inc.Inventor: Anton Leighton
-
Patent number: 8592381Abstract: The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant.Type: GrantFiled: June 14, 2011Date of Patent: November 26, 2013Assignee: Rhamnopharma Inc.Inventor: Anton Leighton
-
Publication number: 20130310330Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.Type: ApplicationFiled: July 19, 2013Publication date: November 21, 2013Inventor: Anton LEIGHTON
-
Publication number: 20110257115Abstract: The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant.Type: ApplicationFiled: June 14, 2011Publication date: October 20, 2011Inventor: Anton Leighton